Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.
about
Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impactTreatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infectionHepatitis B virus reactivation with a rituximab-containing regimenGenetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignThe place of immunotherapy in the management of HCV-induced vasculitis: an updateHepatitis C Therapy in Renal Patients: Who, How, When?Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemiaBroadly neutralizing antibodies abrogate established hepatitis C virus infectionA randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferonCD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency VirusExtrahepatic manifestations of hepatitis C infection: navigating CHASM.Rituximab-based treatment, HCV replication, and hepatic flares.Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection.Hepatitis C virus, cryoglobulinemia, and kidney: novel evidence.Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment.An approach to the patient with retiform purpura.Laboratory testing for cryoglobulins.Management of rheumatic disease with comorbid HBV or HCV infection.Current treatment of hepatitis C-associated rheumatic diseasesNeurological complications of hepatitis C infection.The hepatitis C virus infection as a systemic disease.Viral infections and their management in patients with chronic lymphocytic leukemia.Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV.Hepatitis C virus-induced vasculitis: therapeutic options.A patient with hepatitis C virus infection and inflammatory polyarthritis.Hepatitis C virus infection in end-stage renal disease and kidney transplantation.Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection.Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy.Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection.The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents.Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment.Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infectionLong-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012.Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors.Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy.
P2860
Q22299128-FFA3FDCC-7C99-456C-A92B-58679D3CF28FQ24187162-4C93B369-5F8F-4456-8AEE-D17551485E80Q26785963-74C34A93-1E95-4F54-8925-68FB91DC4DADQ26801759-5D585FD3-22B2-417F-B828-C7C434C0448FQ27015124-8ED3970D-9C32-47A8-9A48-1C0C289F9814Q28077130-206CC3EE-75D5-4953-9311-F8772A5E218CQ34708468-80C8A1AD-769A-45B7-AE36-A177B59CF100Q35032263-9ECC2229-2E61-442A-9F5B-4AFA6520463AQ35624871-64989747-D949-4548-B102-8183D8685C52Q35674649-8E88A7E7-30B0-4207-8BFB-ECE7714B2A8CQ35993488-85EEB32B-3FB8-40CD-A0CD-18EAAD8F2622Q36010828-0FD5FAE8-2820-4206-87D1-51A8937D4965Q36167378-518CD438-B7D1-4C4D-A7E8-9E7564D991E3Q36497753-964FDCA6-53CB-4B68-BFAB-C19B7D8F3692Q37288114-8C7B7102-1626-4D1D-A97C-4EDA7E203488Q37532286-8AA52BBF-7647-4317-9759-0608BBED341FQ37853593-B945A8EB-A36C-448F-A229-89D571AE4769Q37877205-8A41287B-FD73-4E0A-AD5F-A3B86A0685AAQ38008173-18CFB782-5FBD-48D3-AE9A-19A50B48FBCBQ38021493-759DF38F-2D32-414A-AE93-7F2989E7F9BBQ38044680-60A5F1AF-A051-4C98-95D5-BD5A7714CBB2Q38052844-3DF9484F-2FDF-4381-AEFD-90AAE999DEFEQ38064527-046BFBBA-4891-4399-9AFE-CE0D6AD3A720Q38084182-08FA8A51-10A0-4B39-A1C5-C3B388624256Q38127143-AAB17D38-286A-453C-93EC-48C08EAD748CQ38193030-4BFCA0C5-0AB9-46BB-B096-36344750DB3CQ38213956-D3922E09-D43F-4E2C-B492-166B7DECD521Q38298448-44A44EE6-0BE5-4838-8C98-0C5F66EE0C89Q38393228-339448D4-77AE-4B54-A24D-6988FF208B0FQ38656396-C4DE5248-947A-48D5-952D-FAB15BC1A944Q38814211-23C9BA79-7903-4BD8-BDEF-C428DC8672C3Q38909316-3927EFA5-17D2-4CDC-95F6-EA594D01A938Q40528517-9CC75D10-E8EF-4A98-ABC7-41B25FF300E8Q41175619-6EA63B98-1306-465F-A588-3A35AF3CE00BQ41806895-4509E08F-B19D-4E8E-9CFB-5EAB4642692BQ42180401-0BCA1F5F-8969-4897-B205-1CAD824611EBQ42846265-A73132EA-0ED1-41F2-8F4D-D5849C50FDE5Q42981014-1258B98E-F87C-44F0-8A86-0EF3EC84A1A6Q43036468-C858B778-C90B-4DE2-A5D0-684E1DB8AC79Q45361240-61CA776C-A0F5-4239-9EF6-6058784136FB
P2860
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Safety and efficacy of rituxim ...... emia and severe liver disease.
@en
Safety and efficacy of rituxim ...... emia and severe liver disease.
@nl
type
label
Safety and efficacy of rituxim ...... emia and severe liver disease.
@en
Safety and efficacy of rituxim ...... emia and severe liver disease.
@nl
prefLabel
Safety and efficacy of rituxim ...... emia and severe liver disease.
@en
Safety and efficacy of rituxim ...... emia and severe liver disease.
@nl
P2093
P50
P1433
P1476
Safety and efficacy of rituxim ...... nemia and severe liver disease
@en
P2093
Anna Linda Zignego
Antonio Petrarca
Carlo Giannini
Luigi Rigacci
Marco Matucci-Cerinic
Monica Monti
Paolo Montalto
Patrizio Caini
Umberto Arena
P304
P356
10.1182/BLOOD-2009-11-253948
P407
P577
2010-03-22T00:00:00Z